However, one study found that the combination of erlotinib and bevacizumab resulted in a PFS time of 18 weeks in 24 recurrent glioblastoma patients, with 50% of patients showing radiographic response and nearly 30% of patients remaining progression-free at 6 months.215 An even more impressive prospective study has shown that molecular profiling of EGFR and VEGF status in recurrent glioblastoma patients may be a more effective strategy for disease management. This evidence concerns the gene EGFR and glioblastoma.